Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.78 |
| ▸ | SRC | P12931 | 12/20 | 0.78 |
| ▸ | TEK | Q02763 | 11/20 | 0.78 |
| ▸ | KDR | P35968 | 6/20 | 0.78 |
| ▸ | BTK | Q06187 | 4/20 | 0.78 |
| ▸ | EGFR | P00533 | 2/20 | 0.78 |
| ▸ | FYN | P06241 | 2/20 | 0.78 |
| ▸ | LYN | P07948 | 2/20 | 0.78 |
| ▸ | CSK | P41240 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | RGS12 | O14924 | 1/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | GMNN | O75496 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861013 | 1.00 | LCK (0.78) | LCKSRCTEKKDRBTK | |
| SCHEMBL6866055 | 1.00 | LCK (0.78) | LCKSRCTEKKDRBTK | |
| SCHEMBL6868558 | 0.90 | LCK (0.77) | LCKSRCTEKKDRBTK | |
| SCHEMBL23847623 | 0.88 | LCK (0.71) | LCKSRCTEKKDRBTK | |
| SCHEMBL30054109 | 0.88 | LCK (0.71) | LCKSRCTEKKDRBTK | |
| SCHEMBL378454 | 0.88 | SRC (1.00) | LCKSRCTEKKDRBTK | |
| SCHEMBL29920993 | 0.88 | SRC (1.00) | LCKSRCTEKKDRBTK | |
| SCHEMBL24458610 | 0.88 | SRC (0.96) | LCKSRCTEKKDRBTK | |
| SCHEMBL6463904 | 0.88 | LCK (0.74) | LCKSRCTEKKDRBTK | |
| SCHEMBL6463898 | 0.88 | LCK (0.74) | LCKSRCTEKKDRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115298180-B | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 日本理化学研究所 | 2025-06-10 | — | — | CN | disclosed |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| WO-2021188417-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | FLASH THERAPEUTICS, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188417-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | FLASH THERAPEUTICS, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | LCK 6/4885SRC 206/4885TEK 22/4885 |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | LCK 188/4885SRC 95/4885TEK 622/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | LCK 188/4885SRC 95/4885TEK 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.